Thrombophilia Treatment Market Segmentation:
Type Segment Analysis
The oral anticoagulants are projected to garner 36.7% of the thrombophilia treatment market share by 2037, owing to their superior patient compliance and expanded outpatient usage. According to the Centers for Disease Control and Prevention, anticoagulants are the most frequently prescribed drug class, especially in the U.S. The usage of direct oral anticoagulants such as apixaban has garnered dominance as they are eradicating the requirement for frequent blood monitoring. Additionally, oral anticoagulants are getting approval, and patients are witnessing widespread availability of the medicine in oral form.
Drug Class Segment Analysis
The direct oral anticoagulants segment is anticipated to garner 32% of the thrombophilia treatment market share by 2037. The growth of the market can be attributed to its unmatched convenience and superior safety profiles. The traditional options, such as warfarin or injectable heparins, render fixed-dose regimens, eliminating the need for routine blood tests. Also, there has been an expansion in approval from the FDA or EMA for the treatment of thrombophilia conditions. As the healthcare systems are prioritizing outpatient care and opting for DOACs for value-based treatment.
Our in-depth analysis of the global thrombophilia treatment market includes the following segments:
| Segment | Subsegment |
|
Type |
|
|
Drug Class |
|
|
Route of Administration |
|
|
End user |
|
|
Distribution Channel |
|
|
Application |
|
|
Trade Type |
|
